BCIQ Profiles

Company Profile ReportTarget Profile Report
1102 QTs
BioCentury & Getty Images

Product Development

Nov. 2 Quick Takes: EMA reviewing filgotinib and DBV’s peanut allergy therapy; plus Royalty Pharma-CF Foundation, CARSgen, Karyopharm, Aurinia, Regeneron and Astellas 

Nov 3, 2020 | 1:27 AM GMT

EMA reviewing filgotinib for ulcerative colitis
Gilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) said EMA is reviewing its MAA for Jyseleca filgotinib to

Read the full 560 word article

How to gain access

Continue reading with a
two-week free trial.